FDA-approved1,3Evidence: Large human trialsSexual and reproductive health

Bremelanotide1

Also called Vyleesi, PT-1412

Key takeaway

Bremelanotide is a lab-made peptide that activates melanocortin receptors and is the active ingredient in Vyleesi.1,3 It is FDA-approved for one use: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The label states that it is not indicated for postmenopausal women, for men or to enhance sexual performance.1 Two large randomized trials described in the label found small improvements in desire and distress scores, but no difference from placebo in the number of satisfying sexual events.1 Nausea affected 40% of people taking it in those trials, and the label says it is contraindicated in people with uncontrolled high blood pressure or known heart disease.1

Bremelanotide at a glance

What it isA melanocortin receptor agonist. The label states that it activates several receptor subtypes, of which MC1R and MC4R are most relevant.1
FDA statusFDA-approved. Drugs@FDA lists Vyleesi with an original approval date of June 21, 2019, for HSDD in premenopausal women. The cited label has no boxed warning.1,3
Human evidenceTwo identical 24-week randomized, double-blind, placebo-controlled Phase 3 trials described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is bremelanotide?

Bremelanotide is a lab-made peptide that the label describes as a melanocortin receptor agonist. It is also known by its development code, PT-141.1,2

In the United States it is the active ingredient of Vyleesi, according to Drugs@FDA.3

How does bremelanotide work?

The label states that bremelanotide activates several melanocortin receptors and that, at the levels used, binding to MC1R and MC4R is most relevant. MC4R-carrying nerve cells are found in many parts of the brain.1

The label also states that the way it improves HSDD in women is unknown, and that binding to MC1R on pigment cells can increase skin pigmentation.1

What do human studies show?

The label describes two identical randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD, in which 1,267 participants were randomized to bremelanotide or placebo for 24 weeks.1

In both trials, bremelanotide produced a statistically significant increase in a sexual-desire score and a decrease in a score for distress about low desire compared with placebo, according to the label.1

The label reports no significant difference from placebo in the number of satisfying sexual events, a secondary measure.1

More people stopped treatment early in the bremelanotide groups than in the placebo groups: 40% versus 13% in one trial and 39% versus 25% in the other. In the trials, 18% of people taking bremelanotide stopped because of adverse reactions, most often nausea, compared with 2% on placebo.1

What the evidence base contains

  • Large randomized human trial Two identical randomized, double-blind, placebo-controlled Phase 3 trials (NCT02333071 and NCT02338960) that together randomized 1,267 participants, all premenopausal women with acquired, generalized HSDD, with a 24-week placebo-controlled phase.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is bremelanotide FDA-approved?

Yes. Drugs@FDA lists Vyleesi, application NDA210557, with an original approval date of June 21, 2019.3

The Vyleesi label cited here (DailyMed SPL version 1, published November 18, 2025) states that it is indicated for premenopausal women with acquired, generalized HSDD that causes marked distress or difficulty in relationships and is not due to another medical or psychiatric condition, relationship problems or the effects of a medicine.1

The label states that it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance.1

The label has no boxed warning. It states that bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and its warnings cover temporary rises in blood pressure with a fall in heart rate, darkening of patches of skin and gums, and nausea.1

On October 22, 2026, FDA approved a labeling supplement for Vyleesi that, according to the approval letter, updates the label’s section on use in specific populations based on the final report of a required postmarketing study.4

Timeline

  1. FDA approves Vyleesi, according to Drugs@FDA.3
  2. DailyMed publishes the Vyleesi label version cited on this page.1
  3. FDA approves a Vyleesi labeling supplement that updates the label’s section on use in specific populations.4

What is still unknown?

How bremelanotide improves HSDD, which the label says is unknown.1

How meaningful the score changes are for individual women: the label presents supplementary analyses to help interpret them, and many participants stopped treatment early.1

Its effects outside the approved population: the label’s trials enrolled premenopausal women only.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Bremelanotide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Bremelanotide are the records PeptideScanner has selected and published, not every registration or paper about Bremelanotide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Vyleesi for HSDD in premenopausal women. Two large randomized trials described in the label found small improvements in desire and distress scores but no difference in satisfying sexual events. The label states that it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 20, 2026 · Review version 2.

Review source snapshots checked September 20, 2026 · Integrity checked September 20, 2026.

Three selected reports cover a phase 2 dose-finding trial, the two phase 3 RECONNECT trials, and a safety analysis that reuses development-program participants. Other populations and formulations are outside this synthesis.↗↗↗

What the reviewed sources report

RECONNECT reported improvements in desire and related distress in premenopausal women with hypoactive sexual desire disorder. Nausea, flushing and headache were more frequent with bremelanotide. Safety analyses overlap the efficacy-trial population.↗↗↗

What remains unresolved?

  • How do the magnitude of symptom changes, treatment discontinuation and patient preferences affect interpretation?↗↗↗
  • Which longer-term harms and populations remain inadequately characterized?↗↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Vyleesi · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The cited U.S. label covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with specified exclusions. It does not cover men, postmenopausal women or enhancement of sexual performance. Label: 1 ↗

Which safety limits matter?

The label lists uncontrolled hypertension or known cardiovascular disease as contraindications. It describes transient blood-pressure increases, heart-rate reduction, focal hyperpigmentation and nausea. Label: 1, 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18

Label ZIP SHA-256: deb36c45aeecfb5e78f4b9ff837af0dfa1d12acf404c2d0424a6c279343cc780. Extracted XML SHA-256: 40f565dabb4834a5e8ae91adc6836df37b62102e1b94a57aa2bfc74969fa09be.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Bremelanotide?

Manually reviewed September 20, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

Three selected reports cover a phase 2 dose-finding trial, the two phase 3 RECONNECT trials, and a safety analysis that reuses development-program participants. Other populations and formulations are outside this synthesis.123

Bottom line from this bounded source set

RECONNECT reported improvements in desire and related distress in premenopausal women with hypoactive sexual desire disorder. Nausea, flushing and headache were more frequent with bremelanotide. Safety analyses overlap the efficacy-trial population.123

Reviewed study record

RECONNECT: study 301

Design

A randomized, double-blind, placebo-controlled trial assessed changes in desire and related distress during a 24-week treatment period.1

Population

Premenopausal women with hypoactive sexual desire disorder participated. The abstract reports 1,267 randomized participants across both RECONNECT trials, not a separate study 301 total.1

Outcomes reported

Compared with placebo, the reported treatment differences were +0.30 points on the desire measure and −0.37 points on the related-distress measure.1

Limitations

These are study 301 results from the selected abstract. Its combined trial totals and integrated effect estimates must not be assigned to this trial alone. Nausea, flushing and headache were more frequent with bremelanotide in both trials.1

Reviewed study record

RECONNECT: study 302

Design

A randomized, double-blind, placebo-controlled trial assessed changes in desire and related distress during a 24-week treatment period.1

Population

Premenopausal women with hypoactive sexual desire disorder participated. The abstract reports 1,267 randomized participants across both RECONNECT trials, not a separate study 302 total.1

Outcomes reported

Compared with placebo, the reported treatment differences were +0.42 points on the desire measure and −0.29 points on the related-distress measure.1

Limitations

These are study 302 results from the selected abstract. Its combined trial totals and integrated effect estimates must not be assigned to this trial alone. Nausea, flushing and headache were more frequent with bremelanotide in both trials.1

Reviewed study record

Development-program safety analysis

Design

An integrated report reviewed safety across clinical development, including the RECONNECT randomized and open-label periods.2

Population

The program included approximately 3,500 participants across 43 studies; the integrated blinded phase 3 analysis included 1,247.2

Outcomes reported

Nausea was the most common reason for stopping bremelanotide. The report also described transient blood-pressure increases and focal hyperpigmentation.2

Limitations

The integrated data overlap other trial reports and cannot be counted as an independent replication. Open-label continuation introduces selection and attrition.2

Reviewed study record

Phase 2 dose-finding study

Design

A randomized placebo-controlled study assessed outcomes over 12 weeks.3

Population

The efficacy analysis included 327 premenopausal women with female sexual dysfunction.3

Outcomes reported

The pooled active groups improved reported satisfying sexual events and questionnaire measures compared with placebo; nausea, flushing and headache were reported.3

Limitations

Pooled exposure groups, a different primary endpoint and short follow-up limit comparison with phase 3 results. This report is not a head-to-head comparison with another medicine.3

Reviewed source set

  1. PubMed · 31599840Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. ↗PubMed PMID 31599840 · EFetch XML reviewed 2026-09-20 · payload SHA-256 b9b2737876819a52052ecd9dc7208be1ad5712f7a133c5c13d04f6663f02d118
    No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1097/aog.0000000000003500. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 35147466Safety Profile of Bremelanotide Across the Clinical Development Program. ↗PubMed PMID 35147466 · EFetch XML reviewed 2026-09-15 · payload SHA-256 48181697b30706288d7b5eee02328c0a65af95c8b39bc9022273ca1916eb7813
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1089/jwh.2021.0191. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 27181790Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. ↗PubMed PMID 27181790 · EFetch XML reviewed 2026-09-15 · payload SHA-256 2b56148504fb42c6a6ddb2af9b93818c62391301435cd29c35789f40d60e2ea7
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.2217/whe-2016-0018. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

Desire and distress were the supported outcomes

FDA’s 2019 review describes two six-month placebo-controlled trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder. The supported outcomes were modest improvements in reported desire and associated distress. FDA PDF pp. 22, 26 ↗

More findings, study links and document coverage

A related endpoint did not improve

Bremelanotide did not improve the number of satisfying sexual events, a key secondary endpoint. FDA explained why improvement on that measure was not required for this specific indication. FDA PDF pp. 26 ↗

The measurement window affects interpretation

The questionnaires recalled approximately a month, while use in the trials was intermittent. FDA discussed this mismatch when interpreting patient-reported changes; the scores should not be presented as a response to every individual use. FDA PDF pp. 26 ↗

The studied population limits the conclusion

FDA did not establish efficacy in postmenopausal women in this review. Blood-pressure effects, nausea and pigmentation changes were important safety issues, and limited pregnancy information led to further study requirements. FDA PDF pp. 23, 26 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Vyleesi: FDA selected application review ↗

    Selected sections reviewed · fda-bremelanotide-review-2019 · Document/feed date: 2019-06-21

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Vyleesi · NDA 210557 · Document dated 2019-06-21. Identity checked on PDF pp. 5.

    Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.

    Retrieved 2026-09-19. Read PDF pages: 5, 22, 23, 26 of 539. SHA-256: 065ab49b8fbc93c5bbdcff0604d966f2256f177e644b01b82b169a1e74e0e564.

Remaining work

  • Review the pivotal publications, discontinuation patterns and later postmarketing requirements.
  • Reconcile subsequent labeling and pregnancy follow-up without treating the 2019 review as current surveillance.

Open versioned document coverage and study pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary reports of administration to people of the specified peptide; secondary reviews, animal/cell experiments and unrelated acronym matches are outside this scope. Selected summaries do not close the broader screening queue.

112 retrieved · 3 included · 1 excluded · 108 awaiting a decision · 2 full-text appraisals

Search terms, record decisions and remaining work

"bremelanotide"[Title/Abstract] OR "PT-141"[Title/Abstract]

  • Search covers PubMed title/abstract terms; regulator, registry, older aliases, non-indexed and non-English records require separate reconciliation.
  • Full-text appraisal and independent registry comparison remain incomplete.

Showing 25 of 112 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 35147466 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT02333071; NCT02338960; additional-program-studies-unresolved.
  2. PubMed 31599840 — include: Selected human report; main full text and current registry comparison reviewed. Specific supplements, historical comparisons and unresolved issues remain identified in the structured reading. Study families: NCT02333071; NCT02338960.
    Structured full-text reading · PMC6819021

    This is an editorial structured reading, not a validated risk-of-bias score.

    Read the source full text (Europe PMC XML) ↗ · NCT02333071 registry record ↗ · NCT02338960 registry record ↗

    Randomization and masking
    RECONNECT comprised two separate randomized placebo-controlled trials with country-stratified blocks after a placebo run-in. Recognizable nausea could affect masking; the paper did not establish that participants remained unaware of assignment.
    Missing data
    Of 1,267 randomized participants, 1,247 entered safety analyses and 1,202 the modified intention-to-treat analysis. Only 856 completed, with more withdrawals on active treatment. Last-observation-carried-forward primary analyses do not remove attrition concerns.
    Outcome selection
    Desire and distress coprimary measures improved, while the prespecified satisfying-sexual-event count did not (integrated p=0.630). Later hierarchical secondary results are exploratory; a post hoc event percentage is not the failed count endpoint. Nausea occurred in 40.0% versus 1.3%; one hospitalization for vomiting/headache was considered treatment-related.
    Applicability
    The selected premenopausal population was predominantly White and US-based, with stable relationships and psychiatric-treatment exclusions. This does not establish safety or efficacy in excluded populations, including people at higher cardiovascular risk.
    Funding and conflicts
    Palatin sponsored and participated in design, execution, analysis and reporting. The authors reported access to individual and aggregate data; the public data-sharing statement did not offer participant data.
    Registry comparison
    NCT02333071 and NCT02338960 identify the two trials and agree on the coprimary measures. Their randomized flow totals (653 and 614) reconcile the paper; enrollment totals are not randomized counts. One record has inconsistent enrollment fields. Historical versions and linked supplements remain unresolved; the supplement link was unavailable during review.

    Reviewed 2026-09-15; source SHA-256 d939a9d3502b7945efc876a08c392a8d6c4de8cd6a36f2e1dc0c06daa03199bb.

  3. PubMed 27181790 — include: Selected human report; main full text and current registry comparison reviewed. Specific supplements, historical comparisons and unresolved issues remain identified in the structured reading. Study families: NCT01382719.
    Structured full-text reading · PMC5384512

    This is an editorial structured reading, not a validated risk-of-bias score.

    Read the source full text (Europe PMC XML) ↗ · NCT01382719 registry record ↗

    Randomization and masking
    The phase 2 study used diagnosis-stratified interactive randomization to four blinded groups with matching placebo after a placebo baseline period. The authors state placebo response was not used to exclude participants.
    Missing data
    Of 612 enrolled participants, 397 were randomized, 394 treated, 327 met modified efficacy-analysis criteria and 293 completed. Requiring a follow-up assessment excludes some randomized participants; these denominators must remain distinct.
    Outcome selection
    The prespecified pooled active comparison improved monthly satisfying events by 0.7 versus 0.2 (p=0.018). The first hierarchical secondary endpoint failed, so later questionnaire p-values were nominal/exploratory. Three active participants and one placebo participant reported serious events, considered unrelated; protocol blood-pressure withdrawals were reported separately from other adverse-event withdrawals.
    Applicability
    The trial enrolled selected premenopausal women with desire and/or arousal disorders, excluding uncontrolled hypertension and several psychiatric/gynecologic conditions. Its mixed diagnoses and short follow-up differ from the later phase 3 population.
    Funding and conflicts
    Palatin funded the study and editorial assistance. Three authors were company employees and stockholders, and other authors disclosed research or consulting relationships.
    Registry comparison
    NCT01382719 lists 612 enrolled, consistent with enrollment before randomization, and matches the satisfying-event primary endpoint and modified analysis population. The current registry secondary list is not a verification of the paper's claimed testing hierarchy; historical protocol and analysis-plan comparison remains open.

    Reviewed 2026-09-15; source SHA-256 5f3ed19a1ea4f1fb136b35b91fc9f2dbeaa9d4d30f748dc67de198db63cea00f.

  4. PubMed 18179455 — exclude: PubMed marks this report as a retracted publication; excluded from efficacy synthesis.
  5. PubMed 42485063 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  6. PubMed 42340853 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  7. PubMed 41419078 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  8. PubMed 42254382 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  9. PubMed 42041173 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  10. PubMed 41960633 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  11. PubMed 42123471 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  12. PubMed 42021992 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  13. PubMed 42144994 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  14. PubMed 40543759 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  15. PubMed 41088800 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  16. PubMed 41002740 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  17. PubMed 40513668 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  18. PubMed 40518469 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  19. PubMed 40678415 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  20. PubMed 40069591 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  21. PubMed 39793696 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  22. PubMed 39846877 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  23. PubMed 39231849 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  24. PubMed 31369224 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
  25. PubMed 38767282 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.

ClinicalTrials.gov search

ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.

10 retrieved · 10 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

bremelanotide OR PT-141

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:28:08.649410+00:00 · HTTP 200 · SHA-256 2e1d1b1858480e0d26fd2d90d0c907b509621fe4b0e7eae69fde4105b8bd5fee.

  • Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
  • Other registries and unregistered studies are outside this search.

Showing 10 of 10 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT03973047 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT03973047.
  2. ClinicalTrials.gov NCT04179734 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT04179734.
  3. ClinicalTrials.gov NCT06867835 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06867835.
  4. ClinicalTrials.gov NCT00425256 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT00425256.
  5. ClinicalTrials.gov NCT01382719 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01382719.
  6. ClinicalTrials.gov NCT04943068 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT04943068.
  7. ClinicalTrials.gov NCT02333071 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02333071.
  8. ClinicalTrials.gov NCT02338960 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02338960.
  9. ClinicalTrials.gov NCT06565611 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06565611.
  10. ClinicalTrials.gov NCT05709444 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05709444.

FDA search

Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"BREMELANOTIDE" OR products.active_ingredients.name:"BREMELANOTIDE ACETATE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:54:14.071320+00:00 · HTTP 200 · SHA-256 7d89658a268f28a79cc50d21de986d9d429a94f7de82523760c170572ee6a059.

  • This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA210557 — include: The application record contains the queried ingredient; indications, labels and approval documents require their own review.

EMA search

Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary matching of reviewed identity terms: ["bremelanotide", "Vyleesi", "PT-141"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Complete source-document appraisal and national European sources remain open.
  • Zero identity matches apply only to these feed fields and terms.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary matching of reviewed identity terms: ["bremelanotide", "Vyleesi", "PT-141"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

    • Complete source-document appraisal and national European sources remain open.
    • Zero identity matches apply only to these feed fields and terms.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary matching of reviewed identity terms: ["bremelanotide", "Vyleesi", "PT-141"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

      • Complete source-document appraisal and national European sources remain open.
      • Zero identity matches apply only to these feed fields and terms.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        Explore status sources, recent additions, and coverage gaps

        Living status brief

        What is the current status of Bremelanotide?

        FDA-approved as Vyleesi for HSDD in premenopausal women. Two large randomized trials described in the label found small improvements in desire and distress scores but no difference in satisfying sexual events. The label states that it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.↗↗

        The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

        Evidence present

        What records are connected here?

        Evidence lanes
        3
        Source years
        13
        Drugs@FDA applications
        1

        These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

        Coverage gaps

        What remains unknown or unsupported?

        PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

        PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

        Explore the Evidence Map and record counts

        Evidence Map v1

        What kinds of records connect to Bremelanotide?

        Compare collection coverage →

        This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

        32Selected dated records
        35Connected citations
        13Populated source years2011–2026
        3/4Record lanes present

        Registered human studies

        Trial composition

        3 of 6 selected trial records include at least one phase value; 3 of 6 include a status value in the retained structured contract.

        18 public history versions connect to 4 of these trial records across 8 submitted years. Open the record-history collection →

        PhasesPhase 1 1Phase 3 1Phase 4 1
        Status at observationCompleted 3

        A phase value is unavailable here for 3 selected records; this is not counted as “no phase.”

        A status value is unavailable here for 3 selected records; this is not counted as a trial status.

        PubMed bibliography

        Publication composition

        5 of 21 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

        Publication typesJournal Article 5Review 3Research Support, Non-U.S. Gov't 2Randomized Controlled Trial 1

        Bibliography fields unavailable here for 16 selected records; the records remain visible as metadata observations.

        Regulatory and publication surfaces

        What is structurally connected?

        Drugs@FDA applications
        1
        FDA Federal Register documents
        2
        DailyMed SPL versions
        2
        Canonical profile
        Published
        Profile structured data
        Published
        Linked dated records
        32

        Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

        Profile publication history and record counts
        Source records by collection · 32 dated records

        Research hub

        Explore the Bremelanotide evidence record

        Open all 32 records →
        32Dated records
        3Evidence types
        32Cited public sources
        13Source years

        Change ledger

        Recently changed for Bremelanotide

        Open all 35 events →

        PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

        Record added

        Bremelanotide DailyMed SPL version 2

        DailyMed lists Structured Product Labeling version 2 for the reviewed Bremelanotide label family with a published date of 2026-11-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

        PeptideScanner change date
        November 15, 2026
        Cited source date
        November 9, 2026
        Evidence lane
        Regulatory
        Profile status changed

        Bremelanotide profile

        We added a plain-language reader guide with cited answers, re-checked the Vyleesi label, and added the Drugs@FDA approval record and FDA’s October 22, 2026 approval of a labeling supplement.

        PeptideScanner change date
        November 14, 2026
        Evidence lane
        Profile
        Record added

        ClinicalTrials.gov record NCT03973047

        PeptideScanner retained ClinicalTrials.gov record NCT03973047 at 2026-07-30T19:40:58.916Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was bremelanotide.

        PeptideScanner change date
        September 9, 2026
        Cited source date
        April 4, 2022
        Evidence lane
        Clinical trials

        Official-source collections

        Source records for Bremelanotide

        Open the full research atlas →
        PubMed21

        5 with attributed title, venue, publication-date, and type metadata.

        1. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.Expert opinion on pharmacotherapy · 2022 10 18
        2. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022 02 25
        3. Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurology international · 2022 01 04
        Explore all selected literature →
        ClinicalTrials.gov6

        18 public history versions across these dated registry records; status labels apply only to each cited observation.

        1. NCT04943068Registry update November 13, 2024 · completed at observation
        2. NCT05709444Registry update October 17, 2024 · completed at observation
        3. NCT04179734Registry update August 9, 2024 · completed at observation
        Explore all selected trial records →Explore all public record history →

        Evidence types

        Coverage by source year

        Selected records span February 23, 2011 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

        Continue exploring

        Profiles with overlapping source-year coverage

        Open the research atlas →

        These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

        Organizations and trial records named in cited sources

        Organizations named in cited records

        • U.S. National Library of Medicine1
        • U.S. Food and Drug Administration3
        Dated updates connected to this profile · 32

        Updates connected to this profile

        Open the full cross-source timeline →
        1. Regulatory

          Bremelanotide DailyMed SPL version 2↗

          DailyMed lists Structured Product Labeling version 2 for the reviewed Bremelanotide label family with a published date of 2026-11-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

        2. Literature metadata

          PubMed record PMID 42485063↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 42485063 at 2026-08-10T18:13:56.710Z. PubMed recorded a metadata revision date of 2026-07-22 and an Entrez history date of 2026-07-22. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

        3. Literature metadata

          PubMed record PMID 39793696↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 39793696 at 2026-07-30T16:20:39.143Z. PubMed recorded a metadata revision date of 2026-05-24 and an Entrez history date of 2025-01-10. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

        4. Literature metadata

          PubMed record PMID 41960633↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 41960633 at 2026-07-30T16:22:18.490Z. PubMed recorded a metadata revision date of 2026-04-24 and an Entrez history date of 2026-04-10. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗

        5. Regulatory

          Bremelanotide DailyMed SPL version 1↗

          DailyMed lists Structured Product Labeling version 1 for the reviewed Bremelanotide label family with a published date of 2025-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

        6. Clinical trials

          ClinicalTrials.gov record NCT04943068↗

          PeptideScanner retained ClinicalTrials.gov record NCT04943068 at 2026-07-30T18:38:25.522Z. Its registry update date was 2024-11-13, and PeptideScanner's reviewed identity mapping was bremelanotide.↗

        7. Clinical trials

          ClinicalTrials.gov record NCT05709444↗

          PeptideScanner retained ClinicalTrials.gov record NCT05709444 at 2026-07-30T18:39:33.780Z. Its registry update date was 2024-10-17, and PeptideScanner's reviewed identity mapping was bremelanotide.↗

        8. Clinical trials

          ClinicalTrials.gov record NCT04179734↗

          PeptideScanner retained ClinicalTrials.gov record NCT04179734 at 2026-07-30T18:41:37.916Z. Its registry update date was 2024-08-09, and PeptideScanner's reviewed identity mapping was bremelanotide.↗

        9. Literature metadata

          Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.↗

          PubMed lists PMID 32353679 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2020-03-27 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        10. Literature metadata

          An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.↗

          PubMed lists PMID 36242769 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2022-10-18 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        11. Literature metadata

          The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.↗

          PubMed lists PMID 33455598 in CNS spectrums as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-01-18 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        12. Clinical trials

          ClinicalTrials.gov record NCT03973047↗

          PeptideScanner retained ClinicalTrials.gov record NCT03973047 at 2026-07-30T19:40:58.916Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was bremelanotide.↗

        Citations

        Sources

        Coverage and sources →

        Numbered markers in the text point here. Each link opens the original public record.

        1. 1
          VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18 ↗

          DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

        2. 2
          Bremelanotide substance identity record ↗

          FDA Global Substance Registration System · Official source · Source checked July 29, 2026

        3. 3
          Drugs@FDA application NDA210557 · original submission status AP · 2019-06-21 · dataset 2026-08-13 ↗

          Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

        4. 4
          Vyleesi (bremelanotide): NDA 210557 supplement S-005 approval letter, October 22, 2026 ↗

          U.S. Food and Drug Administration · Official source · Source checked November 14, 2026